Breadcrumb Navigation

Melanom: An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma

Stadium/Indikation inkl. Kurzinfo

Melanom – 2nd line

Stadium III oder IV
(Auch mukosales oder Aderhaut-melanom)

TYRP1-Targeting CD3 T-Cell engager

Kurztitel

Roche BP42169
TYRP
NCT04551352

Offizieller Titel

An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma

PI

Prof. Reinhard Dummer

Zuständige Ärztin

Fabienne Fröhlich

Tel. +41 43 253 25 13

Behandelnder Fachbereich

Dermatologische Klinik